Shauna L. Blois

Shauna L. Blois

Auto-generated profile, based on publicly available information

Shauna L. Blois

Department of Clinical Studies Ontario Veterinary College, University of Guelph Guelph Ontario Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2019 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
OGOliver A. Garden
Oliver A. Garden
LKLinda Kidd
Linda Kidd
AMAngela M. Mexas
Angela M. Mexas
YCYu-Mei Ruby Chang
Yu-Mei Ruby Chang
UJUnity Jeffery
Unity Jeffery
BSBalazs Szladovits
Balazs Szladovits
Immune-mediated hemolytic anemia (IMHA) is an important cause of morbidity and mortality in dogs. IMHA also occurs in cats, although less commonly. IMHA is considered secondary when it can be attributed to an underlying disease, and as primary (idiopathic) if no cause is found. Eliminating diseases that cause IMHA may attenuate or stop immune-mediated erythrocyte destruction, and adverse consequences of long-term immunosuppressive treatment can be avoided. Infections, cancer, drugs, vaccines, and inflammatory processes may be underlying causes of IMHA. Evidence for these comorbidities has not been systematically evaluated, rendering evidence-based decisions difficult. We identified and extracted data from studies published in the veterinary literature and developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria for IMHA, comorbidities, and causality. Succinct evidence summary statements were written, along with screening recommendations. Statements were refined by conducting 3 iterations of Delphi review with panel and task force members. Commentary was solicited from several professional bodies to maximize clinical applicability before the recommendations were submitted. The resulting document is intended to provide clinical guidelines for diagnosis of, and underlying disease screening for, IMHA in dogs and cats. These should be implemented with consideration of animal, owner, and geographical factors.

31 March 2021 in Journal of Veterinary Emergency and Critical Care
Verified
Journal Article
Open access
PDF file
EDElizabeth B. Davidow
Elizabeth B. Davidow
SBShauna L. Blois
Shauna L. Blois
IGIsabelle Goy‐Thollot
Isabelle Goy‐Thollot
LHLauren Harris
Lauren Harris
KHKaren Humm
Karen Humm
KWK. Jane Wardrop
K. Jane Wardrop
Objective: To use a systematic, evidence‐based consensus process to develop definitions for transfusion reactions in dogs and cats.Design: Evidence evaluation of the literature was carried out for identified transfusion reaction types in dogs and cats. Reaction definitions were generated based on synthesis of human and veterinary literature. Consensus on the definitions was achieved through Delphi‐style surveys. Draft recommendations were made available through industry specialty listservs and comments were incorporated.Results: Definitions with imputability criteria were developed for 14 types of transfusion reactions.Conclusions: The evidence review and consensus process resulted in definitions that can be used to facilitate future veterinary transfusion reaction research.

10 March 2021 in Journal of Veterinary Emergency and Critical Care
Verified
Journal Article
Open access
PDF file
EDElizabeth B. Davidow
Elizabeth B. Davidow
SBShauna L. Blois
Shauna L. Blois
IGIsabelle Goy‐Thollot
Isabelle Goy‐Thollot
LHLauren Harris
Lauren Harris
KHKaren Humm
Karen Humm
KWK. Jane Wardrop
K. Jane Wardrop
Objective: To systematically review available evidence to develop guidelines for the prevention of transfusion reactions and monitoring of transfusion administration in dogs and cats.Design: Evidence evaluation of the literature (identified through Medline searches through Pubmed and Google Scholar searches) was carried out for identified transfusion reaction types in dogs and cats. Evidence was evaluated using PICO (Population, Intervention, Comparison, Outcome) questions generated for each reaction type. Evidence was categorized by level of evidence (LOE) and quality (Good, Fair, or Poor). Guidelines for prevention and monitoring were generated based on the synthesis of the evidence. Consensus on the final recommendations and a proposed transfusion administration monitoring form was achieved through Delphi‐style surveys. Draft recommendations and the monitoring form were made available through veterinary specialty listservs and comments were incorporated.Results: Twenty‐nine guidelines and a transfusion administration monitoring form were formulated from the evidence review with a high degree of consensusConclusions: This systematic evidence evaluation process yielded recommended prevention and monitoring guidelines and a proposed transfusion administration form. However, significant knowledge gaps were identified, demonstrating the need for additional research in veterinary transfusion medicine.

26 August 2013 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
FPF.M. Park
F.M. Park
SBS.L. Blois
S.L. Blois
AAA.C.G. Abrams-Ogg
A.C.G. Abrams-Ogg
RWR.D. Wood
R.D. Wood
DAD.G. Allen
D.G. Allen
ADA. Downie
A. Downie
Background Dogs with hyperadrenocorticism are at risk of thromboembolic disease, which might be caused by an underlying hypercoagulable state. Hypothesis/Objectives To assess hemostatic function in dogs with ACTH-dependent hyperadrenocorticism (ADHAC) before and after treatment. Animals Nineteen dogs with ADHAC and 40 normal dogs. Methods Prospective, observational study. Dogs with ADHAC were recruited from the referral hospital patient population; normal dogs were recruited from staff and students at the study's institution. Hemostasis was assessed before and at 3 and 6 months after treatment with trilostane (T0, T3, T6) by kaolin-activated thrombelastography with platelet mapping (TEG-PM), prothrombin time, activated partial thromboplastin time, fibrinogen concentration, and antithrombin activity (AT). Results Dogs with ADHAC had statistically significantly increased α-angle (P < .01) and maximum amplitude (MA)thrombin (P < .01) on TEG-PM, and significantly decreased κ (P < .005) at T0, T3, and T6. Platelet count (P < .001) and fibrinogen concentration (P < .001), but not AT activity, were increased in dogs with ADHAC at T0, T3, and T6. Conclusions and Clinical Importance Dogs with ADHAC have thrombelastographic evidence of hypercoagulability and remained hypercoagulable during treatment. AT deficiency does not appear to be involved in the pathogenesis of hypercoagulability in this population.

1 March 2010 in American Journal of Veterinary Research
Verified
Journal Article
Closed access
SBShauna L. Blois
Shauna L. Blois
DADana G. Allen
Dana G. Allen
RWR. Darren Wood
R. Darren Wood
PCPeter D. Conlon
Peter D. Conlon
Objective—To determine effects of therapeutic dosages of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Animals—10 hound-crossbred dogs. Procedures—Aspirin (10 mg/kg, PO, q 12 h), carprofen (4.4 mg/kg, PO, q 24 h), deracoxib (2 mg/kg, PO, q 24 h), meloxicam (0.1 mg/kg, PO, q 24 h), and a placebo were administered for 7 days in a random order to each of 10 healthy dogs; there was a 21-day washout period between subsequent treatments. One-stage prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen concentration, and plasma concentrations of thromboxane (TX)B2 and 6-keto prostaglandin (PG)F1α were measured before and after treatment administration. Platelet function was assessed by use of a platelet-function analyzer and aggregation. Results—Aspirin, carprofen, and meloxicam did not significantly affect platelet function. Deracoxib caused a mild decrease in platelet aggregation induced by 50μM ADP. Platelet number, Hct, PT, aPTT, and plasma TXB2 and 6-keto PGF1α concentrations were unchanged after NSAID administration. Meloxicam administration resulted in a significant decrease in fibrinogen concentration, but results remained within the laboratory reference interval. Conclusions and Clinical Relevance—Oral administration of commonly used NSAIDs at therapeutic dosages in healthy dogs did not alter plasma TXB2 and 6-keto PGF1α concentrations. Deracoxib administration resulted in a minor abnormality in platelet aggregation. Anti-inflammatory doses of aspirin did not affect platelet function as measured by use of optical aggregometry and a platelet-function analyzer. Further evaluation of the effects of aspirin and cyclooxygenase-2–selective inhibitors on hemostasis should be performed.

15 June 2011 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Closed access
SBShauna L. Blois
Shauna L. Blois
EDErica Dickie
Erica Dickie
SKStephen A. Kruth
Stephen A. Kruth
DADana G. Allen
Dana G. Allen
Objective—To characterize a population of dogs from a tertiary care center with 2 or more endocrine disorders, including the specific disorders and time intervals between diagnosis of each disorder. Design—Retrospective case series. Animals—35 dogs with 2 or more endocrine disorders. Procedures—Medical records were reviewed, and the following was recorded: clinical signs, physical examination findings, and the results of CBC, serum biochemical analysis, urinalysis, aerobic bacterial culture of urine samples, endocrine testing, diagnostic imaging, and necropsy. Results—35 dogs with more than 1 endocrine disorder were identified. Seventy-seven percent (27/35) of the dogs were male, and the mean age at the time of diagnosis of the first endocrinopathy was 7.9 years. Miniature Schnauzer was the most common breed. Twenty-eight of 35 (80%) dogs had 2 disorders; 7 (20%) had 3 disorders. The most common combinations of disorders included diabetes mellitus and hyperadrenocorticism in 57.1 % (20/35) of dogs; hypoadrenocorticism and hypothyroidism in 22.9% (8/35) of dogs; and diabetes mellitus and hypothyroidism in 28.6% (10/35) of dogs. A mean of 14.5 months elapsed between diagnosis of the first and second endocrine disorders, whereas there was a mean of 31.1 months between diagnosis of the first and third endocrine disorders. Conclusions and Clinical Relevance—Results suggested that the occurrence of multiple endocrine disorders was uncommon in dogs. The most common combinations of endocrine disorders in this population of dogs were diabetes mellitus and hyperadrenocorticism, followed by hypoadrenocorticism and hypothyroidism.